WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.

Moderator

Frederick J. Raal, MB BCh, FRCP, FCP(SA), Cert Endo, MMED, PhD

Professor and Head
Division of Endocrinology and Metabolism
Department of Medicine
University of the Witwatersrand
Johannesburg, South Africa

Disclosures

Frederick J. Raal, MB BCh, FRCP, FCP(SA), Cert Endo, MMED, PhD, has the following relevant financial relationships:
Consultant or advisor for: Amgen Inc.; LIB Therapeutics; Novartis; Regeneron Pharmaceuticals, Inc.; Sanofi
Speaker or member of speakers bureau for: Amgen Inc.; LIB Therapeutics; Novartis; Regeneron Pharmaceuticals, Inc.; Sanofi
Research funding from: Amgen Inc.; LIB Therapeutics; Novartis; Regeneron Pharmaceuticals, Inc.; Sanofi
Contracted researcher for: Amgen Inc.; LIB Therapeutics; Novartis; Regeneron Pharmaceuticals, Inc.; Sanofi

Faculty

Krzysztof Narkiewicz, MD, PhD

Professor and Head
Department of Hypertension and Diabetology
Medical University of Gdańsk
Gdańsk, Poland

Disclosures

Krzysztof Narkiewicz, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Idorsia Pharmaceuticals, Inc. (former); Janssen
Speaker or member of speakers bureau for: Adamed; Bausch; Berlin-Chemie/Menarini; Egis; Gedeon Richter; Gilead Sciences, Inc.; Krka; Novo Nordisk; Polpharma; Recordati; Sandoz; SERVIER
Research funding from: Idorsia Pharmaceuticals, Inc. (former)

Alberto Zambon, MD, PhD, FAHA

Associate Professor of Medicine
Department of Medicine
University of Padua School of Medicine
Padua, Italy

Disclosures

Alberto Zambon, MD, PhD, FAHA, has the following relevant financial relationships:
Consultant or advisor for: Amarin Corporation plc
Speaker or member of speakers bureau for: Abbott; Alfasigma USA, Inc.; Amarin Corporation plc; Amgen Inc.; Amryt; AstraZeneca; Fidia Pharma USA, Inc.; Mylan Laboratories Inc.; Novartis; Sanofi; SERVIER; Swedish Orphan Biovitrum; Zentiva

Editor

Anne M. Sendaydiego, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Anne M. Sendaydiego, PharmD, has no relevant financial relationships.

Compliance Reviewer

Yaisanet Oyola, MD

Associate Director, Accreditation and Compliance

Disclosures

Yaisanet Oyola, MD, has no relevant financial relationships.

From Medscape Education

Gaining Control With Early Combination Lipid-Lowering Therapy: Applying Learnings From the Queen's Gambit

Authors: Frederick J. Raal, MB BCh, FRCP, FCP(SA), Cert Endo, MMED, PhD; Krzysztof Narkiewicz, MD, PhD; Alberto Zambon, MD, PhD, FAHAFaculty and Disclosures

processing....

Posted: 05/02/2023

This educational activity is intended for an international audience of cardiologists, primary care physicians, endocrinologists/diabetologists, nephrologists, and nurses.

The goal of this activity is for the learner to be better able to discuss the need for early combination lipid-lowering therapy (LLT) in patients with dyslipidemia.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Recommendations for the use of early combination therapy in patients with dyslipidemia
- Benefits of using early combination therapy in dyslipidemia management
Have greater competence related to
- The early initiation of combination LLT in patients with dyslipidemia

Page 1 of 5

Practice Assessment

Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Moderator

Frederick J. Raal, MB BCh, FRCP, FCP(SA), Cert Endo, MMED, PhD

Faculty

Krzysztof Narkiewicz, MD, PhD

Alberto Zambon, MD, PhD, FAHA

Editor

Anne M. Sendaydiego, PharmD

Compliance Reviewer

Yaisanet Oyola, MD

Gaining Control With Early Combination Lipid-Lowering Therapy: Applying Learnings From the Queen's Gambit